Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report
2018
Mattei, Alexia | Magalon, Jeremy | Bertrand, Baptiste | Grimaud, Fanny | Révis, Joana | Velier, Melanie | Veran, Julie | Dessi, Patrick | Sabatier, Florence | Giovanni, Antoine | Hôpital de la Conception [CHU - APHM] (LA CONCEPTION) | Laboratoire Parole et Langage (LPL) ; Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS) | Vascular research center of Marseille (VRCM) ; Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM) | Aix-Marseille Université - Faculté de pharmacie (AMU PHARM) ; Aix Marseille Université (AMU) | Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN) ; Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM) | Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES) ; Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS) | The project was promoted by the Assistance Publique des Hopitaux de Marseille, with a funding from the Fondation de l’Avenir pour la Recherche Médicale Appliquée (Paris, France) and the Fondation des Gueules Cassées.
International audience
显示更多 [+] 显示较少 [-]英语. Patients with scarred vocal folds (congenitally or following phonosurgery) are currently difficult to treat and present a dysphonia, often disabling in daily life. Several therapies are available on the market but the results of these are often disappointing. The autologous adipose-derived stromal vascular fraction (ADSVF) is recognized as an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. We present here the case of a 43-year-old woman who had a severe dysphonia associated with scarred vocal folds after a phonosurgery and was resistant to conventional medical and surgical treatments. She received a local administration of autologous ADSVF. The protocol involved, on the same day, adipose tissue extraction, ADSVF preparation, and then local injection (0.45ml of ADSVF in each vocal fold, for a total of 12.2 million ADSVF viable cells). No serious adverse events have been described. One year following the surgery, the laryngoscopic aspect and the majority of voice parameters had improved, in particular the Voice Handicap Index decreasing from 75 to 9. The perceptual analysis found the voice to be less hoarse and more stable, without breathiness. The case of this patient highlights the therapeutic potential of ADSVF for such applications (trial registration, ClinicalTrials.gov NCT02622464; registered 4 December 2015).
显示更多 [+] 显示较少 [-]